Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia

Childhood Acute Lymphoblastic Leukemia Clinical Trial

Official title: Philadelphia -Negative High-risk Children Acute Lymphoblastic Leukemia(ALL) Treatment:Induction Therapy:Vincristine(V),Idarubicin(I),L-asparaginase(L),Dexamethasone(D);Consolidation:V+Daunorubicin(D)+L+D, Methotrexate,Cytarabine

Status Recruiting

Clinical Trial Summary

The cure rate for childhood acute lymphoblastic leukemia (ALL) has increased significantly in recent decades and expected cure rates now exceed 85%. In recent years, Tyrosine Kinase Inhibitor(TKI) has improved outcome of Philadelphia chromosome positive (Ph+)ALL . But in some high risk groups, The prognosis of patients is still very bad and the relapse rate is high. Clearly, new therapies are urgently needed to prevent and /or treat relapsed ALL.

Clinical Trial Description

1. The prognosis of childhood acute lymphoblastic leukemia(ALL) has been increased.

2. Tyrosine Kinase Inhibitor(TKI) has improved Philadelphia chromosome positive (Ph+)ALL treatment outcome.

3. The prognosis of high-risk childhood ALL except for Philadelphia chromosome positive (Ph+)ALL is very bad. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• B-cell Childhood Acute Lymphoblastic Leukemia
• Childhood Acute Lymphoblastic Leukemia
• Leukemia
• Leukemia, Lymphoid
• Philadelphia Chromosome
• Philadelphia Chromosome, Ph^1^, Absent
• Precursor Cell Lymphoblastic Leukemia-Lymphoma

• NCT number: NCT01990807
• Study type: Interventional
• Source: Chinese Academy of Medical Sciences
• Contact: Xiaofan Zhu, MD
• Phone: +86-22-23909001
• Email: xfzhu1981@126.com
• Status: Recruiting
• Phase: Phase 4
• Start date: October 2012
• Completion date: October 2014